Aclaris Therapeutics Receives FDA Approval for Eskata (hydrogen peroxide) Topical Solution, 40% (w/w) for the Treatment of Raised Seborrheic Keratoses

MALVERN, Pa., Dec. 15, 2017 (GLOBE NEWSWIRE) — Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a dermatologist-led biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has approved Eskata (hydrogen peroxide) topical…

Pharmaceutical Stocks

[stock-ticker]

© 2018 Drugs News All rights reserved.       Privacy Policy       Contact Us